Moderna Stock vs Competition: Who Wins?
Moderna‘s (MRNA) stock has seen mixed performance over the past year, outperforming Pfizer (PFE) and Sarepta (SRPT) but lagging Alnylam (ALNY) in returns. A closer examination of the provided data as of January 16, 2026, reveals significant profitability challenges for Moderna, marked by negative operating and free cash flow margins, alongside a substantial decline in revenue growth. Its negative price-to-earnings ratio further underscores these losses. While some peers exhibit positive margins and growth, Moderna faces considerable hurdles in restoring profitability and achieving consistent revenue growth, which could limit its near-term upside in a dynamic biotech sector.
- MRNA’s -157.3% operating margin (lowest, PFE 24.6%) signals severe operational challenges post-pandemic, hindering core profitability.
- MRNA’s -56.4% LTM revenue decline, lagging peers, indicates sharp post-pandemic demand fall and pipeline diversification struggles.
- MRNA’s 23.9% stock gain on a -5.2 PE, despite peer ALNY’s stronger returns, points to speculative investor bets amid unprofitability.
Here’s how Moderna stacks up across size, valuation, and profitability versus key peers.
| MRNA | PFE | ALNY | SRPT | |
|---|---|---|---|---|
| Market Cap ($ Bil) | 16.3 | 145.8 | 47.2 | 2.1 |
| Revenue ($ Bil) | 2.2 | 62.8 | 3.2 | 2.4 |
| PE Ratio | -5.2 | 14.8 | 1,084.0 | -7.8 |
| LTM Revenue Growth | -56.4% | 3.9% | 53.2% | 47.1% |
| LTM Operating Margin | -157.3% | 24.6% | 8.2% | -3.6% |
| LTM FCF Margin | -120.9% | 16.5% | 6.9% | -16.1% |
| 12M Market Return | 23.9% | 3.8% | 44.2% | -81.9% |
For more details on Moderna, read Buy or Sell MRNA Stock. Below we compare MRNA’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -56.4% | -52.6% | -64.2% | 6.4% |
| PFE | 3.9% | 6.8% | -41.1% | 24.5% |
| ALNY | 53.2% | 23.0% | 76.2% | 22.9% |
| SRPT | 47.1% | 53.0% | 33.3% | 32.9% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -157.3% | -123.3% | -62.8% | 49.9% |
| PFE | 24.6% | 23.3% | 7.1% | 36.7% |
| ALNY | 8.2% | -7.9% | -15.4% | -75.7% |
| SRPT | -3.6% | 11.5% | -21.5% | -57.5% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| MRNA | -5.2 | -3.2 | -3.4 | 4.7 |
| PFE | 14.8 | 17.6 | 70.7 | 5.1 |
| ALNY | 1084.0 | -182.5 | -66.8 | -20.6 |
| SRPT | -7.8 | 9.9 | -21.0 | -12.0 |
Still not sure about MRNA stock? Consider portfolio approach.
Move Beyond Single Stocks With A Multi Asset Portfolio
Individual stocks can soar or tank but multi asset exposure steadies the ride. A spread out portfolio captures upside while limiting the damage from any one market.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices